These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 23719297)

  • 1. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.
    de Lavallade H; Khoder A; Hart M; Sarvaria A; Sekine T; Alsuliman A; Mielke S; Bazeos A; Stringaris K; Ali S; Milojkovic D; Foroni L; Chaidos A; Cooper N; Gabriel I; Apperley J; Belsey S; Flanagan RJ; Goldman J; Shpall EJ; Kelleher P; Marin D; Rezvani K
    Blood; 2013 Jul; 122(2):227-38. PubMed ID: 23719297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.
    Rajala HLM; Missiry ME; Ruusila A; Koskenvesa P; Brümmendorf TH; Gjertsen BT; Janssen J; Lotfi K; Markevärn B; Olsson-Strömberg U; Stenke L; Stentoft J; Richter J; Hjorth-Hansen H; Kreutzman A; Mustjoki S
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1543-1554. PubMed ID: 28337541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
    Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
    Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
    Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
    Front Immunol; 2018; 9():3152. PubMed ID: 30705677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
    Cassuto O; Dufies M; Jacquel A; Robert G; Ginet C; Dubois A; Hamouda A; Puissant A; Luciano F; Karsenti JM; Legros L; Cassuto JP; Lenain P; Auberger P
    Oncotarget; 2012 Dec; 3(12):1557-65. PubMed ID: 23238683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.
    Rohon P; Porkka K; Mustjoki S
    Eur J Haematol; 2010 Nov; 85(5):387-98. PubMed ID: 20662899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
    Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
    J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?
    Agrawal M; Garg RJ; Kantarjian H; Cortes J
    Curr Oncol Rep; 2010 Sep; 12(5):302-13. PubMed ID: 20640942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic myeloid leukemia elderly patients in the tyrosine kinase inhibitor era.
    Russo D; Malagola M; Skert C; Filì C; Bergonzi C; Cancelli V; Cattina F
    Curr Cancer Drug Targets; 2013 Sep; 13(7):755-67. PubMed ID: 23941515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloid leukemia: First-line drug of choice.
    Jabbour E
    Am J Hematol; 2016 Jan; 91(1):59-66. PubMed ID: 26769227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
    El Missiry M; Adnan Awad S; Rajala HL; Al-Samadi A; Ekblom M; Markevän B; Åstrand-Grundström I; Wold M; Svedahl ER; Juhl BR; Bjerrum OW; Haulin I; Porkka K; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S
    J Cancer Res Clin Oncol; 2016 May; 142(5):1041-50. PubMed ID: 26746653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
    Tinsley SM
    J Clin Nurs; 2010 May; 19(9-10):1207-18. PubMed ID: 20345830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.